Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Anticoagulation in Deep Venous Thrombosis: Current Trends in the Era of Non- Vitamin K Antagonists Oral Anticoagulants

Author(s): Panteleimon E. Papakonstantinou, Costas Tsioufis*, Dimitris Konstantinidis, Panagiotis Iliakis, Ioannis Leontsinis and Dimitrios Tousoulis

Volume 26, Issue 23, 2020

Page: [2692 - 2702] Pages: 11

DOI: 10.2174/1381612826666200420150517

Price: $65

Abstract

Anticoagulation therapy is the cornerstone of treatment in acute vein thrombosis (DVT) and it aims to reduce symptoms, thrombus extension, DVT recurrences, and mortality. The treatment for DVT depends on its anatomical extent, among other factors. Anticoagulation therapy for proximal DVT is clearly recommended (at least for 3 months), while AT for isolated distal DVT should be considered, especially in the presence of high thromboembolic risk factors. The optimal anticoagulant and duration of therapy are determined by the clinical assessment, taking into account the thromboembolic and bleeding risk in each patient in a case-by-case decision making. Non-Vitamin K antagonists oral anticoagulants (NOACs) were a revolution in the anticoagulation management of DVT. Nowadays, NOACs are considered as first-line therapy in the anticoagulation therapy for DVT and are recommended as the preferred anticoagulant agents by most scientific societies. NOACs offer a simple route of administration (oral agents), a rapid onset-offset of their action along with a good efficacy and safety profile in comparison with Vitamin K Antagonists (VKAs). However, there are issues about their efficacy and safety profile in specific populations with high thromboembolic and bleeding risks, such as renal failure patients, active-cancer patients, and pregnant women, in which VKAs and heparins were the standard care of treatment. Since the available data are promising for the use of NOACs in end-stage chronic kidney disease and cancer patients, several ongoing randomized trials are currently trying to solve that issues and give evidence about the safety and efficacy of NOACs in these populations.

Keywords: Deep vein thrombosis, DVT, venous thromboembolism, VTE, anticoagulation, anticoagulants, NOACs, DOACs.

« Previous Next »
[1]
Kim V, Spandorfer J. Epidemiology of venous thromboembolic disease. Emerg Med Clin North Am 2001; 19(4): 839-59.
[http://dx.doi.org/10.1016/S0733-8627(05)70221-2] [PMID: 11762274]
[2]
White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107(23)(Suppl. 1): I4-8.
[PMID: 12814979]
[3]
Goldhaber SZ, Tapson VF. DVT FREE Steering Committee. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol 2004; 93(2): 259-62.
[http://dx.doi.org/10.1016/j.amjcard.2003.09.057] [PMID: 14715365]
[4]
Murin S, Romano PS, White RH. Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism. Thromb Haemost 2002; 88(3): 407-14.
[http://dx.doi.org/10.1055/s-0037-1613230] [PMID: 12353068]
[5]
Raskob GE, Angchaisuksiri P, Blanco AN, et al. ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol 2014; 34(11): 2363-71.
[http://dx.doi.org/10.1161/ATVBAHA.114.304488] [PMID: 25304324]
[6]
Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ III. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158(6): 585-93.
[http://dx.doi.org/10.1001/archinte.158.6.585] [PMID: 9521222]
[7]
Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991; 151(5): 933-8.
[http://dx.doi.org/10.1001/archinte.1991.00400050081016] [PMID: 2025141]
[8]
Mazzolai L, Aboyans V, Ageno W, et al. Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. Eur Heart J 2018; 39(47): 4208-18.
[http://dx.doi.org/10.1093/eurheartj/ehx003] [PMID: 28329262]
[9]
White RH, Zhou H, Romano PS. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med 1998; 128(9): 737-40.
[http://dx.doi.org/10.7326/0003-4819-128-9-199805010-00006] [PMID: 9556467]
[10]
Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016; 149(2): 315-52.
[http://dx.doi.org/10.1016/j.chest.2015.11.026] [PMID: 26867832]
[11]
Papakonstantinou PE, Simantirakis EN. Long-term rhythm monitoring with an implantable loop recorder in patients after the first clinical atrial fibrillation episode. Towards an individualized management. Minerva Cardioangiol 2019; 67(2): 121-30.
[http://dx.doi.org/10.23736/S0026-4725.19.04883-7] [PMID: 30724269]
[12]
Mearns ES, Coleman CI, Patel D, et al. Index clinical manifestation of venous thromboembolism predicts early recurrence type and frequency: a meta-analysis of randomized controlled trials. J Thromb Haemost 2015; 13(6): 1043-52.
[http://dx.doi.org/10.1111/jth.12914] [PMID: 25819920]
[13]
Konstantinides SV, Torbicki A, Agnelli G. et al.2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014;; 35: 3033--69. 3069a-3069k
[14]
Heit JA, O’Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002; 162(11): 1245-8.
[http://dx.doi.org/10.1001/archinte.162.11.1245] [PMID: 12038942]
[15]
Tran HA, Gibbs H, Merriman E, et al. New guidelines from the Thrombosis and Haemostasis Society of Australia and New Zealand for the diagnosis and management of venous thromboembolism 2019; 210: 227-35.
[http://dx.doi.org/10.5694/mja2.50004]
[16]
Kruger PC, Eikelboom JW, Douketis JD, Hankey GJ. Deep vein thrombosis: update on diagnosis and management. Med J Aust 2019; 210(11): 516-24.
[http://dx.doi.org/10.5694/mja2.50201] [PMID: 31155730]
[17]
Papakonstantinou PE, Asimakopoulou NI, Papadakis JA, et al. Frailty Status Affects the Decision for Long-Term Anticoagulation Therapy in Elderly Patients with Atrial Fibrillation. Drugs Aging 2018; 35(10): 897-905.
[http://dx.doi.org/10.1007/s40266-018-0587-6] [PMID: 30203312]
[18]
Ioannou P, Tsagkaraki E, Andrianaki AM, Papadakis JA. Unnecessary hospitalizations for DVT in the era of NOACs. Eur J Intern Med 2017; 44: e40-1.
[http://dx.doi.org/10.1016/j.ejim.2017.07.026] [PMID: 28739351]
[19]
Streiff MB, Agnelli G, Connors JM, et al. Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis 2016; 41(1): 32-67.
[http://dx.doi.org/10.1007/s11239-015-1317-0] [PMID: 26780738]
[20]
Stubbs MJ, Mouyis M, Thomas M. Deep vein thrombosis. BMJ 2018; 360: k351.
[http://dx.doi.org/10.1136/bmj.k351] [PMID: 29472180]
[21]
Papakonstantinou PE, Asimakopoulou NI, Gargeraki A, Gaitanis KS, Mintzaridis E. Anticoagulation management in non-valvular atrial fibrillation in rural and remote Crete. A single-center study from the region of Sitia. Hellenic J Cardiol 2016; S1109-9666(16): 30152-X.
[http://dx.doi.org/10.1016/j.hjc.2016.05.005] [PMID: 27666753]
[22]
Schulman S, Kearon C, Kakkar AK, et al. RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361(24): 2342-52.
[http://dx.doi.org/10.1056/NEJMoa0906598] [PMID: 19966341]
[23]
Schulman S, Kearon C, Kakkar AK, et al. RE-MEDY Trial Investigators; RE-SONATE Trial Investigators.. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368(8): 709-18.
[http://dx.doi.org/10.1056/NEJMoa1113697] [PMID: 23425163]
[24]
Bauersachs R, Berkowitz SD, Brenner B, et al. EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363(26): 2499-510.
[http://dx.doi.org/10.1056/NEJMoa1007903] [PMID: 21128814]
[25]
Agnelli G, Buller HR, Cohen A, et al. AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369(9): 799-808.
[http://dx.doi.org/10.1056/NEJMoa1302507] [PMID: 23808982]
[26]
Büller HR, Décousus H, Grosso MA, et al. Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369(15): 1406-15.
[http://dx.doi.org/10.1056/NEJMoa1306638] [PMID: 23991658]
[27]
Goldhaber SZ, Schellong S, Kakkar A, et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thromb Haemost 2016; 116(4): 714-21.
[PMID: 27411591]
[28]
Cohen AT. Extended thromboprophylaxis with betrixaban: a new standard for acute medically ill patients. Eur Heart J Suppl 2018; 20(Suppl. E): E1-2.
[http://dx.doi.org/10.1093/eurheartj/suy014] [PMID: 29977161]
[29]
van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124(12): 1968-75.
[http://dx.doi.org/10.1182/blood-2014-04-571232] [PMID: 24963045]
[30]
Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med 2015; 373(25): 2413-24.
[http://dx.doi.org/10.1056/NEJMoa1510991] [PMID: 26559317]
[31]
Cuker A, Burnett A, Triller D, et al. Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum. Am J Hematol 2019; 94(6): 697-709.
[http://dx.doi.org/10.1002/ajh.25475] [PMID: 30916798]
[32]
Levy JH, Douketis J, Weitz JI. Reversal agents for non-vitamin K antagonist oral anticoagulants. Nat Rev Cardiol 2018; 15(5): 273-81.
[http://dx.doi.org/10.1038/nrcardio.2017.223] [PMID: 29345686]
[33]
Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy 2018; 2: 3257-91.
[http://dx.doi.org/10.1182/bloodadvances.2018024893]
[34]
Erkens PM, Prins MH. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2010; (9): CD001100
[http://dx.doi.org/10.1002/14651858.CD001100.pub3] [PMID: 20824828]
[35]
Büller HR, Davidson BL, Decousus H, et al. Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349(18): 1695-702.
[http://dx.doi.org/10.1056/NEJMoa035451] [PMID: 14585937]
[36]
Palareti G, Schellong S. Isolated distal deep vein thrombosis: what we know and what we are doing. J Thromb Haemost 2012; 10(1): 11-9.
[http://dx.doi.org/10.1111/j.1538-7836.2011.04564.x] [PMID: 22082302]
[37]
Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol 2007; 44(2): 62-9.
[http://dx.doi.org/10.1053/j.seminhematol.2007.02.004] [PMID: 17433897]
[38]
Donadini MP, Dentali F, Pegoraro S, et al. Long-term recurrence of venous thromboembolism after short-term treatment of symptomatic isolated distal deep vein thrombosis: A cohort study. Vasc Med 2017; 22(6): 518-24.
[http://dx.doi.org/10.1177/1358863X17720531] [PMID: 28732457]
[39]
Masuda EM, Kistner RL, Musikasinthorn C, Liquido F, Geling O, He Q. The controversy of managing calf vein thrombosis. J Vasc Surg 2012; 55(2): 550-61.
[http://dx.doi.org/10.1016/j.jvs.2011.05.092] [PMID: 22032881]
[40]
Hughes MJ, Stein PD, Matta F. Silent pulmonary embolism in patients with distal deep venous thrombosis: systematic review. Thromb Res 2014; 134(6): 1182-5.
[http://dx.doi.org/10.1016/j.thromres.2014.09.036] [PMID: 25312342]
[41]
Gillet JL, Perrin MR, Allaert FA. Short-term and mid-term outcome of isolated symptomatic muscular calf vein thrombosis. J Vasc Surg 2007; 46(3): 513-9.
[http://dx.doi.org/10.1016/j.jvs.2007.04.040] [PMID: 17681715]
[42]
Righini M, Galanaud JP, Guenneguez H, et al. Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial. Lancet Haematol 2016; 3(12): e556-62.
[http://dx.doi.org/10.1016/S2352-3026(16)30131-4] [PMID: 27836513]
[43]
Parisi R, Visonà A, Camporese G, et al. Isolated distal deep vein thrombosis: efficacy and safety of a protocol of treatment. Treatment of Isolated Calf Thrombosis (TICT) Study. Int Angiol 2009; 28(1): 68-72.
[PMID: 19190559]
[44]
Ferrara F, Meli F, Amato C, et al. Optimal duration of treatment in surgical patients with calf venous thrombosis involving one or more veins. Angiology 2006; 57(4): 418-23.
[http://dx.doi.org/10.1177/0003319706290745] [PMID: 17022376]
[45]
Pinede L, Ninet J, Duhaut P, et al. Investigators of the “Durée Optimale du Traitement AntiVitamines K” (DOTAVK) Study. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 2001; 103(20): 2453-60.
[http://dx.doi.org/10.1161/01.CIR.103.20.2453] [PMID: 11369685]
[46]
Sartori M, Migliaccio L, Favaretto E, Palareti G, Cosmi B. Two years outcome of isolated distal deep vein thrombosis. Thromb Res 2014; 134(1): 36-40.
[http://dx.doi.org/10.1016/j.thromres.2014.03.033] [PMID: 24713107]
[47]
De Martino RR, Wallaert JB, Rossi AP, Zbehlik AJ, Suckow B, Walsh DB. A meta-analysis of anticoagulation for calf deep venous thrombosis. J Vasc Surg 2012; 56(1): 228-37.e1.
[http://dx.doi.org/10.1016/j.jvs.2011.09.087] [PMID: 22209612]
[48]
Galanaud JP, Sevestre MA, Genty C, et al. OPTIMEV-SFMV investigators. Incidence and predictors of venous thromboembolism recurrence after a first isolated distal deep vein thrombosis. J Thromb Haemost 2014; 12(4): 436-43.
[http://dx.doi.org/10.1111/jth.12512] [PMID: 24450376]
[49]
Hansson PO, Sörbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000; 160(6): 769-74.
[http://dx.doi.org/10.1001/archinte.160.6.769] [PMID: 10737276]
[50]
Boutitie F, Pinede L, Schulman S, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials. BMJ 2011; 342: d3036.
[http://dx.doi.org/10.1136/bmj.d3036] [PMID: 21610040]
[51]
Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007; 92(2): 199-205.
[http://dx.doi.org/10.3324/haematol.10516] [PMID: 17296569]
[52]
Kovacs MJ, Kahn SR, Wells PS, et al. Patients with a first symptomatic unprovoked deep vein thrombosis are at higher risk of recurrent venous thromboembolism than patients with a first unprovoked pulmonary embolism. J Thromb Haemost 2010; 8(9): 1926-32.
[http://dx.doi.org/10.1111/j.1538-7836.2010.03958.x] [PMID: 20561184]
[53]
Agnelli G, Prandoni P, Santamaria MG, et al. Warfarin Optimal Duration Italian Trial Investigators. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001; 345(3): 165-9.
[http://dx.doi.org/10.1056/NEJM200107193450302] [PMID: 11463010]
[54]
Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation 2010; 121(14): 1630-6.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.109.925214] [PMID: 20351233]
[55]
Tosetto A, Iorio A, Marcucci M, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost 2012; 10(6): 1019-25.
[http://dx.doi.org/10.1111/j.1538-7836.2012.04735.x] [PMID: 22489957]
[56]
Kyrle PA, Eichinger S. Clinical scores to predict recurrence risk of venous thromboembolism. Thromb Haemost 2012; 108(6): 1061-4.
[PMID: 22872143]
[57]
Weitz JI, Lensing AWA, Prins MH, et al. EINSTEIN CHOICE Investigators. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Engl J Med 2017; 376(13): 1211-22.
[http://dx.doi.org/10.1056/NEJMoa1700518] [PMID: 28316279]
[58]
Agnelli G, Buller HR, Cohen A, et al. AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368(8): 699-708.
[http://dx.doi.org/10.1056/NEJMoa1207541] [PMID: 23216615]
[59]
Chokesuwattanaskul R, Thongprayoon C, Tanawuttiwat T, Kaewput W, Pachariyanon P, Cheungpasitporn W. Safety and efficacy of apixaban versus warfarin in patients with end-stage renal disease: Meta-analysis. Pacing Clin Electrophysiol 2018; 41(6): 627-34.
[http://dx.doi.org/10.1111/pace.13331] [PMID: 29577340]
[60]
Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009; 37(1): 74-81.
[http://dx.doi.org/10.1124/dmd.108.023143] [PMID: 18832478]
[61]
Schafer JH, Casey AL, Dupre KA, Staubes BA. Safety and Efficacy of Apixaban Versus Warfarin in Patients With Advanced Chronic Kidney Disease. Ann Pharmacother 2018; 52(11): 1078-84.
[http://dx.doi.org/10.1177/1060028018781853] [PMID: 29871510]
[62]
Siontis KC, Zhang X, Eckard A, et al. Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States. Circulation 2018; 138(15): 1519-29.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.035418] [PMID: 29954737]
[63]
Zhang L, Steckman DA, Adelstein EC, et al. Oral Anticoagulation for Atrial Fibrillation Thromboembolism Prophylaxis in the Chronic Kidney Disease Population: the State of the Art in 2019. Cardiovasc Drugs Ther 2019; 33(4): 481-8.
[http://dx.doi.org/10.1007/s10557-019-06885-x] [PMID: 31165356]
[64]
Stanton BE, Barasch NS, Tellor KB. Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment. Pharmacotherapy 2017; 37(4): 412-9.
[http://dx.doi.org/10.1002/phar.1905] [PMID: 28117916]
[65]
Godino C, Melillo F, Rubino F, et al. INSIghT investigators. Real-world 2-year outcome of atrial fibrillation treatment with dabigatran, apixaban, and rivaroxaban in patients with and without chronic kidney disease. Intern Emerg Med 2019; 14(8): 1259-70.
[http://dx.doi.org/10.1007/s11739-019-02100-9] [PMID: 31073827]
[66]
Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100(10): 3484-8.
[http://dx.doi.org/10.1182/blood-2002-01-0108] [PMID: 12393647]
[67]
Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166(4): 458-64.
[http://dx.doi.org/10.1001/archinte.166.4.458] [PMID: 16505267]
[68]
Walker AJ, Card TR, West J, Crooks C, Grainge MJ. Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases. Eur J Cancer 2013; 49(6): 1404-13.
[http://dx.doi.org/10.1016/j.ejca.2012.10.021] [PMID: 23146958]
[69]
Cronin-Fenton DP, Søndergaard F, Pedersen LA, et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. Br J Cancer 2010; 103(7): 947-53.
[http://dx.doi.org/10.1038/sj.bjc.6605883] [PMID: 20842120]
[70]
Agnelli G. Direct Oral Anticoagulants for Thromboprophylaxis in Ambulatory Patients with Cancer. N Engl J Med 2019; 380(8): 781-3.
[http://dx.doi.org/10.1056/NEJMe1816060] [PMID: 30786193]
[71]
Mahajan A, Brunson A, White R, Wun T. The Epidemiology of Cancer-Associated Venous Thromboembolism: An Update. Semin Thromb Hemost 2019; 45(4): 321-5.
[http://dx.doi.org/10.1055/s-0039-1688494] [PMID: 31041801]
[72]
White RH, Zhou H, Murin S, Harvey D. Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb Haemost 2005; 93(2): 298-305.
[http://dx.doi.org/10.1160/TH04-08-0506] [PMID: 15711746]
[73]
Posch F, Königsbrügge O, Zielinski C, Pabinger I, Ay C. Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res 2015; 136(3): 582-9.
[http://dx.doi.org/10.1016/j.thromres.2015.07.011] [PMID: 26210891]
[74]
Riess H, Prandoni P, Harder S, Kreher S, Bauersachs R. Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: Potential for drug-drug interactions. Crit Rev Oncol Hematol 2018; 132: 169-79.
[http://dx.doi.org/10.1016/j.critrevonc.2018.09.015] [PMID: 30447923]
[75]
Agnelli G, Gussoni G, Bianchini C, et al. PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009; 10(10): 943-9.
[http://dx.doi.org/10.1016/S1470-2045(09)70232-3] [PMID: 19726226]
[76]
Lyman GH, Khorana AA, Kuderer NM, et al. American Society of Clinical Oncology Clinical Practice. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 31(17): 2189-204.
[http://dx.doi.org/10.1200/JCO.2013.49.1118] [PMID: 23669224]
[77]
Farge D, Bounameaux H, Brenner B, et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 2016; 17(10): e452-66.
[http://dx.doi.org/10.1016/S1470-2045(16)30369-2] [PMID: 27733271]
[78]
Mandalà M, Falanga A, Roila F. ESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2011; 22(Suppl. 6): vi85-92.
[http://dx.doi.org/10.1093/annonc/mdr392] [PMID: 21908511]
[79]
Lee AY, Levine MN, Baker RI, et al. Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349(2): 146-53.
[http://dx.doi.org/10.1056/NEJMoa025313] [PMID: 12853587]
[80]
Akl EA, Kahale L, Barba M, et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2014; (7): CD006650
[http://dx.doi.org/10.1002/14651858.CD006650.pub4] [PMID: 25004410]
[81]
Hull RD, Pineo GF, Brant RF, et al. LITE Trial Investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006; 119(12): 1062-72.
[http://dx.doi.org/10.1016/j.amjmed.2006.02.022] [PMID: 17145251]
[82]
Romera A, Cairols MA, Vila-Coll R, et al. A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg 2009; 37(3): 349-56.
[http://dx.doi.org/10.1016/j.ejvs.2008.11.030] [PMID: 19121589]
[83]
Lee AYY, Kamphuisen PW, Meyer G, et al. CATCH Investigators. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. JAMA 2015; 314(7): 677-86.
[http://dx.doi.org/10.1001/jama.2015.9243] [PMID: 26284719]
[84]
Young AM, Marshall A, Thirlwall J, et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol 2018; 36(20): 2017-23.
[http://dx.doi.org/10.1200/JCO.2018.78.8034] [PMID: 29746227]
[85]
Raskob GE, van Es N, Verhamme P, et al. Hokusai VTE Cancer Investigators. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med 2018; 378(7): 615-24.
[http://dx.doi.org/10.1056/NEJMoa1711948] [PMID: 29231094]
[86]
Key NS, Khorana AA, Kuderer NM, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 2019.Jco1901461
[PMID: 31381464]
[87]
Carrier M, Abou-Nassar K, Mallick R, et al. AVERT Investigators. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N Engl J Med 2019; 380(8): 711-9.
[http://dx.doi.org/10.1056/NEJMoa1814468] [PMID: 30511879]
[88]
Khorana AA, Soff GA, Kakkar AK, et al. CASSINI Investigators. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. N Engl J Med 2019; 380(8): 720-8.
[http://dx.doi.org/10.1056/NEJMoa1814630] [PMID: 30786186]
[89]
Scheres LJJ, Bistervels IM, Middeldorp S. Everything the clinician needs to know about evidence-based anticoagulation in pregnancy. Blood Rev 2019; 33: 82-97.
[http://dx.doi.org/10.1016/j.blre.2018.08.001] [PMID: 30107951]
[90]
Simcox LE, Ormesher L, Tower C, Greer IA. Pulmonary thrombo-embolism in pregnancy: diagnosis and management. Breathe (Sheff) 2015; 11(4): 282-9.
[http://dx.doi.org/10.1183/20734735.008815] [PMID: 27066121]
[91]
Richter C, Sitzmann J, Lang P, Weitzel H, Huch A, Huch R. Excretion of low molecular weight heparin in human milk. Br J Clin Pharmacol 2001; 52(6): 708-10.
[http://dx.doi.org/10.1046/j.0306-5251.2001.01517.x] [PMID: 11736885]
[92]
Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012.
[93]
Nelson-Piercy C, Powrie R, Borg JY, et al. Tinzaparin use in pregnancy: an international, retrospective study of the safety and efficacy profile. Eur J Obstet Gynecol Reprod Biol 2011; 159(2): 293-9.
[http://dx.doi.org/10.1016/j.ejogrb.2011.08.005] [PMID: 21945573]
[94]
Galambosi PJ, Kaaja RJ, Stefanovic V, Ulander VM. Safety of low-molecular-weight heparin during pregnancy: a retrospective controlled cohort study. Eur J Obstet Gynecol Reprod Biol 2012; 163(2): 154-9.
[http://dx.doi.org/10.1016/j.ejogrb.2012.05.010] [PMID: 22658765]
[95]
Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005; 106(2): 401-7.
[http://dx.doi.org/10.1182/blood-2005-02-0626] [PMID: 15811953]
[96]
Warkany J. A warfarin embryopathy? Am J Dis Child 1975; 129(3): 287-8.
[PMID: 1121959]
[97]
Cotrufo M, De Feo M, De Santo LS, et al. Risk of warfarin during pregnancy with mechanical valve prostheses. Obstet Gynecol 2002; 99(1): 35-40.
[PMID: 11777507]
[98]
Vitale N, De Feo M, De Santo LS, Pollice A, Tedesco N, Cotrufo M. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol 1999; 33(6): 1637-41.
[http://dx.doi.org/10.1016/S0735-1097(99)00044-3] [PMID: 10334435]
[99]
Knol HM, Schultinge L, Erwich JJ, Meijer K. Fondaparinux as an alternative anticoagulant therapy during pregnancy. J Thromb Haemost 2010; 8(8): 1876-9.
[http://dx.doi.org/10.1111/j.1538-7836.2010.03926.x] [PMID: 20492464]
[100]
Dempfle CE. Minor transplacental passage of fondaparinux in vivo. N Engl J Med 2004; 350(18): 1914-5.
[http://dx.doi.org/10.1056/NEJM200404293501825] [PMID: 15115845]
[101]
Cohen H, Arachchillage DR, Middeldorp S, Beyer-Westendorf J, Abdul-Kadir R. Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH. J Thromb Haemost 2016; 14(8): 1673-6.
[http://dx.doi.org/10.1111/jth.13366] [PMID: 27346676]
[102]
Beyer-Westendorf J, Michalski F, Tittl L, et al. Pregnancy outcome in patients exposed to direct oral anticoagulants - and the challenge of event reporting. Thromb Haemost 2016; 116(4): 651-8.
[PMID: 27384740]
[103]
Kucher N. Clinical practice. Deep-vein thrombosis of the upper extremities. N Engl J Med 2011; 364(9): 861-9.
[http://dx.doi.org/10.1056/NEJMcp1008740] [PMID: 21366477]
[104]
Joffe HV, Kucher N, Tapson VF, Goldhaber SZ. Deep Vein Thrombosis (DVT) FREE Steering Committee. Upper-extremity deep vein thrombosis: a prospective registry of 592 patients. Circulation 2004; 110(12): 1605-11.
[http://dx.doi.org/10.1161/01.CIR.0000142289.94369.D7] [PMID: 15353493]
[105]
Muñoz FJ, Mismetti P, Poggio R, et al. RIETE Investigators. Clinical outcome of patients with upper-extremity deep vein thrombosis: results from the RIETE Registry. Chest 2008; 133(1): 143-8.
[http://dx.doi.org/10.1378/chest.07-1432] [PMID: 17925416]
[106]
Isma N, Svensson PJ, Gottsäter A, Lindblad B. Upper extremity deep venous thrombosis in the population-based Malmö thrombophilia study (MATS). Epidemiology, risk factors, recurrence risk, and mortality. Thromb Res 2010; 125(6): e335-8.
[http://dx.doi.org/10.1016/j.thromres.2010.03.005] [PMID: 20406709]
[107]
Owens CA, Bui JT, Knuttinen MG, Gaba RC, Carrillo TC. Pulmonary embolism from upper extremity deep vein thrombosis and the role of superior vena cava filters: a review of the literature. J Vasc Interv Radiol 2010; 21(6): 779-87.
[http://dx.doi.org/10.1016/j.jvir.2010.02.021] [PMID: 20434365]
[108]
Spencer FA, Emery C, Lessard D, Goldberg RJ. Worcester Venous Thromboembolism Study. Upper extremity deep vein thrombosis: a community-based perspective. Am J Med 2007; 120(8): 678-84.
[http://dx.doi.org/10.1016/j.amjmed.2006.06.046] [PMID: 17679126]
[109]
Woller SC, Stevens SM, Johnson SA, et al. Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis (ARMDVT): Methods of a prospective single-arm management study. Res Pract Thromb Haemost 2019; 3(3): 340-8.
[http://dx.doi.org/10.1002/rth2.12208] [PMID: 31294320]
[110]
Schiffer CA, Mangu PB, Wade JC, et al. Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013; 31(10): 1357-70.
[http://dx.doi.org/10.1200/JCO.2012.45.5733] [PMID: 23460705]
[111]
Debourdeau P, Farge D, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost 2013; 11(1): 71-80.
[http://dx.doi.org/10.1111/jth.12071] [PMID: 23217208]
[112]
Sousa B, Furlanetto J, Hutka M, et al. ESMO Guidelines Committee. Central venous access in oncology: ESMO Clinical Practice Guidelines. Ann Oncol 2015; 26(Suppl. 5): v152-68.
[http://dx.doi.org/10.1093/annonc/mdv296] [PMID: 26314776]
[113]
Davies GA, Lazo-Langner A, Gandara E, et al. A prospective study of Rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2). Thromb Res 2018; 162: 88-92.
[http://dx.doi.org/10.1016/j.thromres.2017.04.003] [PMID: 28416213]
[114]
Laube ES, Mantha S, Samedy P, Wills J, Harnicar S, Soff GA. Treatment of central venous catheter-associated deep venous thrombosis in cancer patients with rivaroxaban. Am J Hematol 2017; 92(1): E9-E10.
[http://dx.doi.org/10.1002/ajh.24588] [PMID: 27766659]
[115]
Cires-Drouet R, Sharma J, McDonald T, Sorkin JD, Lal BK. Variability in the management of line-related upper extremity deep vein thrombosis. Phlebology 2019; 34(8): 552-8.
[http://dx.doi.org/10.1177/0268355519827155] [PMID: 30704347]

Rights & Permissions Print Cite
Article Metrics
24
3
© 2024 Bentham Science Publishers | Privacy Policy